Implications of polyadenylation in health and disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Polyadenylation is the RNA processing step that completes the maturation of nearly all eukaryotic mRNAs. It is a two-step nuclear process that involves an endonucleolytic cleavage of the pre-mRNA at the 3'-end and the polymerization of a polyadenosine (polyA) tail, which is fundamental for mRNA stability, nuclear export and efficient translation during development. The core molecular machinery responsible for the definition of a polyA site includes several recognition, cleavage and polyadenylation factors that identify and act on a given polyA signal present in a pre-mRNA, usually an AAUAAA hexamer or similar sequence. This mechanism is tightly regulated by other cis-acting elements and trans-acting factors, and its misregulation can cause inefficient gene expression and may ultimately lead to disease. The majority of genes generate multiple mRNAs as a result of alternative polyadenylation in the 3'-untranslated region. The variable lengths of the 3' untranslated regions created by alternative polyadenylation are a recognizable target for differential regulation and clearly affect the fate of the transcript, ultimately modulating the expression of the gene. Over the past few years, several studies have highlighted the importance of polyadenylation and alternative polyadenylation in gene expression and their impact in a variety of physiological conditions, as well as in several illnesses. Abnormalities in the 3'-end processing mechanisms thus represent a common feature among many oncological, immunological, neurological and hematological disorders, but slight imbalances can lead to the natural establishment of a specific cellular state. This review addresses the key steps of polyadenylation and alternative polyadenylation in different cellular conditions and diseases focusing on the molecular effectors that ensure a faultless pre-mRNA 3' end formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Argonaute HITS-CLIP decodes microRNA–mRNA interaction maps
Chi, S. W., Zang, J. B., Mele, A., & Darnell, R. B. (2009) · Nature · doi:10.1038/nature08170 · Cited by 1,791
Mayr, C., & Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.06.016 · Cited by 1,613 · cited 3×
“Indeed, the shortest mRNA isoform of the protooncogene insulin-like growth factor 2 mRNA binding protein 1 (IMP-1) was shown to promote higher oncogenic transformation levels than its longest mRNA isoform.(15) The increase in mRNAs with shorter 30UTRs observed in proliferative conditions(16) was also confirmed in prim…”
BackgroundSandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A., & Burge, C. B. (2008) · Science · doi:10.1126/science.1155390 · Cited by 1,349
Mechanisms and Consequences of Alternative Polyadenylation
Di Giammartino, D. C., Nishida, K., & Manley, J. L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.017 · Cited by 737
Poly(A)-tail profiling reveals an embryonic switch in translational control
Subtelny, A. O., Eichhorn, S. W., Chen, G. R., Sive, H., & Bartel, D. P. (2014) · Nature · doi:10.1038/nature13007 · Cited by 664 · cited 1×
“Two different deep sequencing methods were recently developed to show that the mean pA tail length is generally much shorter: »30 nucleotides in yeast and »50–100 nucleotides in mammalian and Drosophila cell lines.(6,7) Surprisingly, a strong correlation between the length of the pA tail and translation efficiency cou…”
MethodU1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation
Kaida, D., Berg, M. G., Younis, I., Kasim, M., Singh, L. N., Wan, L., & Dreyfuss, G. (2010) · Nature · doi:10.1038/nature09479 · Cited by 638 · cited 8×
“Therefore, in addition to its role in splicing, U1 snRNP binds to nascent premRNAs to prevent premature cleavage and polyadenylation in cryptic PAS.110,113 Interestingly, the U1snRNP levels may be responsible for this event in activated neurons.”
BackgroundInfluentialTAIL-seq: Genome-wide Determination of Poly(A) Tail Length and 3′ End Modifications
Chang, H., Lim, J., Ha, M., & Kim, V. N. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.007 · Cited by 454
Sugawara, T., Holt, J. A., Driscoll, D., Strauss, J. F., Lin, D., Miller, W. L., Patterson, D., Clancy, K. P., Hart, I. M., & Clark, B. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4778 · Cited by 382
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease
Bai, B., Hales, C. M., Chen, P.-C., Gozal, Y., Dammer, E. B., Fritz, J. J., Wang, X., Xia, Q., Duong, D. M., Street, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310249110 · Cited by 335 · cited 1×
“Recently, an extracellular aggregation of U1snRNP components in the neuronal cell bodies of the brains of AD patients that caused defects in RNA processing was described.(115) These results indicate that U1snRNP function in splicing and polyadenylation plays a significant role in AD.”
BackgroundEpstein, L. F., & Orme-Johnson, N. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55054-7 · Cited by 247
Alternative polyadenylation: New insights from global analyses
Shi, Y. (2012) · RNA · doi:10.1261/rna.035899.112 · Cited by 212
RNA polymerase II kinetics in polo polyadenylation signal selection
Pinto, P. A. B., Henriques, T., Freitas, M. O., Martins, T., Domingues, R. G., Wyrzykowska, P. S., Coelho, P. A., Carmo, A. M., Sunkel, C. E., Proudfoot, N. J., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.156 · Cited by 136
Self-citationTee, M.-K., Lin, D., Sugawara, T., Holt, J. A., Guiguen, Y., Buckingham, B., Strauss, J. F., & Miller, W. L. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.12.2299 · Cited by 122
Lin, D., Gitelman, S. E., Saenger, P., & Miller, W. L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115520 · Cited by 120
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Alternative cleavage and polyadenylation in health and disease
Gruber, A. J., & Zavolan, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0145-z · Cited by 472
Post-transcriptional regulation of gene expression and human disease
Corbett, A. H. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.02.011 · Cited by 189
RBBP6 activates the pre-mRNA 3′ end processing machinery in humans
(2022) · doi:10.1101/gad.349223.121 · Cited by 61
Lewis, M., Prouzet‐Mauléon, V., Lichou, F., Richard, E., Iggo, R., Turcq, B., & Mahon, F. (2020) · Cancer Medicine · doi:10.1002/cam4.3231 · Cited by 19
Metadata
- Authors
- Curinha, A., Oliveira Braz, S., Pereira-Castro, I., Cruz, A., & Moreira, A.
- Venue
- Nucleus
- Publisher
- Informa UK Limited
- Published
- 2014-10-31
- Volume
- 5
- Issue
- 6
- Pages
- 508-519
- ISSN
- 1949-1034 (ISSN-L)
- 1949-1042
- OpenAlex
- W2165518330
- Cited by
- 137
- References
- 15
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.